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Background: Aim was to describe the clinical manifestations, diagnosis, histological types and
treatment outcomes of primary thyroid lymphomas (PTLs) in Saudi population.
Materials and methods: Retrospective review of medical records of patients with thyroid
carcinoma, who were treated in our center in the period from July 2005 to December 2012, was
performed. Demographic, diagnostic (pathological and radiologic), histopathological and
treatment parameters were collected.
Results: Among 570 records of patients with thyroid carcinoma, seven (1.23%) patients were
diagnosed with PTLs. The frequent clinical presentation was a neck swelling and compression
symptoms. Four (57.2%) patients were diffuse large B cell lymphomas (DLBCL); two (28.6%)
patients were marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphomas and
one (14.2%) patient with T-cell lymphoma. All patients were treated with chemotherapy
and involved ﬁeld radiotherapy 36–40 Gy in 18–20 fractions. Median follow up was 41.6 months
(12–96) with overall survival and disease free survival rates of 71.1% and 83.3%.
Conclusion: PTLs are uncommon and MALT lymphomas tend to better outcomes than other
variants. However, efforts are required for incorporation of immunohistochemical methods and
multimodality approach to improve the diagnosis and treatment outcomes.
& 2013 The Authors. Published by Elsevier Ltd. All rights reserved.The Authors. Published by Elsevier Ltd. All rights reserved.
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Primary thyroid lymphomas (PTLs) represent 2–8% of all thyroid
malignancies and 1–2% of all extranodal lymphomas [1].
Thyroid gland is devoid of lymphoid tissue and PTLs are
thought to develop from lymphocytes, that are acquired
during the course of a chronic inﬂammatory or autoimmune
thyroiditis (Hashimoto's disease) [2]. Most PTL are diffuse non-
Hodgkin's B cell lymphoma (DLBCL), following by Hodgkin's
lymphomas (HL), T cell lymphomas (TCL) and rarely marginal
zone B-cell mucosa-associated lymphoid tissue (MALT) lym-
phomas [3].
The most common sites for extranodal DLBCL of the head
and neck are Waldeyer's ring and the salivary glands. The
thyroid gland is rare site and most are stage IE or IIE at
diagnosis. The management of thyroid DLBCL is similar to
nodal DLBCL with chemotherapy followed by radiotherapy [4].
Primary involvement of thyroid gland by HL is rare and
only very few cases are reported of classical HL and nodular
sclerosing subtypes and stage IIE [5].
Primary TCL are extremely rare at less than 2% of all PTLs
and are diagnosed at bulky stage IE are managed with
chemotherapy, radiotherapy and surgery [6].
Thyroid MALT lymphoma is one of the rare variants, which
was ﬁrst described by Isaacson and Wright in 1984 [7].
Primary thyroid MALT lymphomas are recognized as extra-
nodal marginal zone B-cell lymphomas in the Revised
European American Lymphoma classiﬁcation of 1994 and
the World Health Organization classiﬁcation of 1999 [8].
Median age of presentation for PTLs is 6th and 7th decade
of life and presenting complaints are generally neck swel-
ling and compression symptoms (dysphagia or hoarseness of
voice). PTLs are considered to respond better to multi-
modality treatments as compared to other type of lympho-
mas [9].
The present study aimed to evaluate the clinical, patho-
logical, radiological and treatment outcomes of patients
with PTLs in Saudi population.
2. Materials and methods
After formal approval from institutional ethical committee,
medical charts of 570 patients with conﬁrmed pathologic
diagnosis of thyroid carcinoma were reviewed, who were
treated in our hospital during period of July 2005 and
December 2012 using computer data based system. Patients
with PTLs were retrieved in the following manner: Demographic data (age at diagnosis, gender and sympto-
matology). Histopathological characteristics: For thyroid DCBCL and
MALT lymphoma immunohistochemical positivity for
CD20, CD45, CD15, and CD30 from ﬁne needle aspiration
(FNA) biopsy, core biopsy and surgery and the presence
of small lymphoid cells. For Tcell lymphoma, appearance
of diffusely inﬁltrating lymphocytes with immunopositiv-
ity T-cell markers (CD3 and CD45) and for Hodgkin's
lymphomas, presence of Reed Sternberg cells with
immunopositivity for CD15 and CD30. Clinical stage, according to Musshoff's modiﬁcation of
Ann Arbor staging system [10] by ﬁndings from physicalexamination, hematological tests and electrolytes, com-
puted tomography (CT) scan of neck, chest and bone
marrow examination ﬁndings. Treatment modalities (surgery, chemotherapy and radia-
tion therapy) and outcomes. Disease-free survival (DFS) was deﬁned as the duration
between the completion of treatment and the date of
documented disease recurrence, death resulting from
the cancer, and/or last follow-up visit (censored). Over-
all survival (OS) was deﬁned as the duration between the
completion of treatment and the date of patient death
or last follow-up visit (censored).
3. Results
Among 570 diagnosed thyroid carcinoma patients, seven
(1.23%) patients with PTLs were found. The patients'
characteristics are listed in Table 1. Median age of patients
with PTLs was 60.8 years (42–77). Six (85.7%) patients were
females and one (14.3%) patient was male. Frequent pre-
sentation was rapidly enlarging neck swelling and associated
compression symptoms (dysphagia or hoarseness) with or
without cervical lymphadenopathy. Six patients had marked
diffuse enlargement of the thyroid gland with retrosternal
extension on preoperative CT neck and chest (Fig. 1). All
patients had initial FNA and four patients had additional
core biopsy of affected thyroid lobe for pathologic con-
ﬁrmation. Two patients proceeded with upfront surgery in
form of thyroidectomy for conﬁrmation of diagnosis. Among
seven patients of PTLs, four (57.2%) were primary DLBCL,
two (28.6%) were primary MALT lymphoma and one (14.2%)
patient was with TCL (Fig. 2). Five (71.5%) patients had
pathological background of Hashimoto's thyroiditis.
Patients with PTLs were treated with rituximab, cyclo-
phosphamide, doxorubicin, vincristine, prednisolone (R-
CHOP) or rituximab, cyclophosphamide, vincristine, and
prednisone (R-CVP) regimen, 4–8 cycles followed by
involved ﬁeld radiotherapy (IFRT). Median radiation doses
were between 36 and 40 Gy in 18–20 fractions using three
dimensional conformal radiation therapy (3DCRT) techni-
ques (Fig. 3).
Median follow up was 41.6 months (12–96). Primary MALT
thyroid lymphomas were found to have better outcome as
compared to other variants. Only one patient with DLBCL
relapsed in right cheek region within 1 year of completion of
treatment and was given salvage chemotherapy (patient
4 in Table 1). DFS and OS rates were 71.1% and 83.3%
respectively.
4. Discussion
This is the ﬁrst report of clinicopathological features and
treatment outcomes of PTLs in a large cohort of thyroid
carcinoma patients from Saudi Arabia. PTLs are rare with
diverse clinicopathological features and treatment outcomes.
PTLs were seen 1.23% of all patients with thyroid carcinoma
in our study population. PTLs were seen to affect elderly
females (85.7%) and in contrast to other studies from Saudi
Arabia, our patients presented with an early stages [11].
Majority of patients with PTL had DLBCL variant followed by
Fig. 1 Computed tomography of head and neck showing marked diffuse enlargement of the thyroid gland with retrosternal
extension. The thyroid gland showing multiple large mostly ill-deﬁned hypodense nodules those are seen mainly in the isthmus and
the left lobe of the gland.
Fig. 2 Histopathological features of (A) DLBCL {presence of diffuse large B cells on Hematoxylin and Eosin staining  200
magniﬁcation}, (B) MALT lymphoma {presence of small lymphoid cells in MALT lymphomaon Hematoxylin and Eosin staining  200
magniﬁcation} and (C) TCL showing CD45 positivity on immunohistochemistry.
Table 1 Patient's characteristics.
Number Age at
presentation
(years)
Gender Presentation Type Stage Treatment Radiotherapy Status at
last visit
1 60 F Neck swelling
dyspnea
DLCBL IIE R-CHOP 8 cycles 36 Gy in 18
fractions
CR alive
2 42 F Neck swelling DLBCL IIE Total thyroidectomy-
R-CHOP 8 cycles
40 Gy in 20
fractions
CR alive
3 72 F Neck swelling DLBCL IE R-CHOP 4 cycles 40 Gy in 20
fractions
CR alive
4 50 F Neck swelling
hoarseness
DLBCL IIE R-CHOP 8 cycles 36 Gy in 18
fractions
Relapse
dead
5 70 F Neck swelling MALT
lymphoma
IE RCVP 3-R-CHOP 3 40 Gy in 20
fractions
CR alive
6 77 M Neck swelling TCL IIE R-CHOP 8 cycles 40 Gy in 20
fractions
Dead
7 55 F Neck swelling MALT IE Right hemi-thyroidectomy
-R-CVP 8 cycles
40 Gy in 20
fractions
CR alive
Abbreviations: DLBCL=diffuse large B cell lymphoma, MALT=mucosa associated lymphoid tissue lymphoma, TCL=T cell lymphoma,
CR=complete response, Gy=gray.
M.A. Tunio et al.16MALT lymphoma similar to other published data [2]. Further-
more, majority of our patients had background of Hashimoto's
thyroiditis on pathological specimens.
PTLs were treated with multimodality approach (standard
chemotherapy regimen and radiation therapy) and debulking
surgery was performed for compression symptoms. Howeversurgery should not be performed in routine in patients with
PTLs without compression symptoms, as PTLs respond well
with chemotherapy and radiotherapy [12].
Overall DFS (83.3%) and OS (71.1%) rates were better than
other reported series. Possible explanation might be (a) early
stage PTLs, (b) use of rituximab based chemotherapy and
Fig. 3 Three dimensional conformal radiotherapy (3DCRT) plan of involved ﬁeld radiotherapy (IFRT) showing 95% isodose
distribution in axial and sagittal images.
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our patients.
In conclusion, PTLs are rare with considerable hetero-
geneous behavior and clinicopathologic features and
treatment outcomes in Saudi population are similar to
Western series. Efforts are required for the incorporation
of immunohistochemical testing for prompt diagnosis and
treatment.
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